Three million children in the U.S. could benefit from Prescribed Pediatric Extended Care (PPEC), but most families don’t know it exists. Jeffrey Soffen, CEO of Spark Pediatrics, the largest PPEC provider in the country, joins McGuireWoods partner Tim Fry on The Corner Series.

Jeff explains how today’s standard of care leaves 40 to 60 percent of skilled nursing hours unfulfilled, forcing medically complex children to remain hospitalized for upward of 500 days. Spark’s model places children in community-based centers for skilled nursing, therapies and peer socialization. Tune in for Jeff’s perspective on state-by-state legislative expansion, health system partnership and why you can do well by doing good in Medicaid.

RS2 Healthcare Partners has invested in KMM Group, according to a news release.

KMM, founded in 2020 and based in Hatboro, Pennsylvania, is a contract manufacturer specializing in components for the medical device industry and other markets.

RS2, founded in 1989 and based in Boston, focuses on healthcare investing in the lower middle market. Formerly Riverside Partners, the firm focuses on pharma services, medical device contract manufacturing and technology-enabled healthcare, among other subsectors. 

Terms of the investment were not disclosed.

SkyKnight Capital has entered into a definitive agreement to invest in Apex Infusion, according to a news release.

Apex, founded in 2006 and headquartered in Signal Hill, California, is an infusion provider that delivers therapies to patients across a network of ambulatory infusion suites and in-home care.

SkyKnight Capital, founded in 2015 and with locations in Burlingame, California and New York, is a private equity firm focused on healthcare and a few other sectors. The firm seeks to invest $25 million to $250 million or higher in companies to acquire 25% to 75% or higher equity ownership.

Apex’s management team will retain a significant ownership stake, and FFL Partners, an existing investor in the company, will remain a minority investor.

Terms of the investment were not disclosed.

Warburg Pincus has announced that a Warburg Pincus-led investor group has agreed to acquire a controlling interest in PANTHERx Rare from Nautic Partners, General Atlantic and The Vistria Group, supported by a material minority investment from a subsidiary of the Abu Dhabi Investment Authority.

Nautic Partners and PANTHERx management will remain significant shareholders alongside the new investor group, while General Atlantic and The Vistria Group are exiting their positions.

PANTHERx Rare, founded in 2011 and based in Pittsburgh, Pennsylvania, is an independent rare pharmacy.

Warburg Pincus, founded in 1966 and based in New York, is a global private equity firm focused on growth investing. The firm takes a long-term perspective and invests in businesses at all stages of development within healthcare and several other sectors.

Nautic, based in Providence, Rhode Island, is a middle market private equity firm focused on investments in healthcare and a few other sectors. The firm prefers to make $50 million to $500 million-plus equity commitments in a variety of buyout, growth and consolidation opportunities of North American companies, targeting EBITDA of $10 million to $100 million-plus.

General Atlantic, founded in 1980 and based in New York, is a global growth equity firm that prefers to make more substantial investments from a dollars perspective in healthcare and a number of other sectors. The firm pursues healthcare investments in the provider services, life sciences/pharmaceutical industry, hospitals/major facilities and non-reimbursement industries. 

The Vistria Group, founded in 2013 and based in Chicago, focuses on making investments in middle market companies in healthcare and a few other industries. The firm pursues control and minority equity investments and prefers to make more substantial investments from a dollars perspective in companies with at least $100 million in revenue.

Terms of the transaction were not disclosed. Industry reports valued the transaction at more than $7 billion.

SkyKnight Capital has announced the close of its fifth fund.

The fund — SkyKnight Capital Fund V — closed with $2 billion in commitments.

SkyKnight Capital, founded in 2015 and with locations in Burlingame, California and New York, is a private equity firm focused on healthcare and a few other sectors. The firm seeks to invest $25 million to $250 million or higher in companies to acquire 25% to 75% or higher equity ownership.

As private equity investment in healthcare compliance and wellness accelerates, oversight infrastructure helps nonphysician providers to scale. Dr. Christopher Seitz, CEO and CMO of GuardianMD, joins John Bradburn, a partner at Elements Health Investors, to discuss mid-level providers reshaping access to care. 

Chris details Guardian’s role in helping clinicians navigate licensing rules. Guardian launched five years ago to build compliance infrastructure for telemedicine and outpatient providers. John explains Elements’ thesis of backing companies that improve outcomes at lower cost.

McGuireWoods partner and host Geoff Cockrell steers the conversation toward AI’s growing role in medical oversight, calling it a massive opportunity. John closes by addressing misconceptions about private equity in healthcare and outlining Guardian’s growth strategy.

Frazier Healthcare Partners will acquire MatrixCare from Resmed, according to a news release.

MatrixCare, founded in 1982 and based in Bloomington, Minnesota, is a provider of cloud-based EHR software for out-of-hospital care settings, including skilled nursing, senior living, home health, hospice and life plan communities.

Frazier, founded in 1991 and based in Seattle, is a provider of private equity capital to healthcare companies. The firm prefers to make more substantial investments from a dollars perspective and pursues a wide range of investment types, including company creation and venture capital to buyouts of profitable lower-middle market companies.

Resmed (NYSE & ASX: RMD), founded in 1989 and based in San Diego, is a global medical device and digital health company that specializes in cloud-connected equipment for treating sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions primarily outside the hospital setting.

Terms of the transaction, which is expected to be completed during the third quarter of 2026, were not disclosed.

McGuireWoods has published the agenda for its 19th Annual Healthcare Growth & Operations Conference (HealthcareGO), set for Sept. 15-16, 2026, at The Ritz-Carlton in Charlotte.

The conference is focused on healthcare operations for C-level executives, founders, consultants and principals in the healthcare and life sciences industries, private equity funds, operations-focused companies and investment bankers.

The program includes bootcamps, roundtables, general sessions and breakout panels.

The full agenda is available here.

Regal Healthcare Capital Partners has announced the close of its fourth private equity fund.

The fund — RHCP IV — closed at $610 million of total commitments and closed above its original target of $550 million.

Regal, founded in 2018 and based in New York, is a control growth equity and buyout firm focused exclusively on lower middle market healthcare services companies. The firm targets multi-site and/or provider-led businesses with revenue between $20 million and $100 million and EBITDA between $2 million and $10 million.

Altaris has announced it will acquire the Life Sciences & Healthcare business (LS&H) from Clarivate (NYSE: CLVT) for $600 million.

LS&H is comprised of the Cortellis and Decision Resources Group portfolios. LS&H is an AI-enabled data intelligence products and services business supporting R&D and commercialization decisions for pharmaceutical, biotechnology and medical technology companies. 

Altaris, founded in 2002 and based in New York, seeks control and minority equity investments exclusively in healthcare. The firm targets companies within the life sciences/pharmaceutical, provider services and non-reimbursement healthcare industries. Altaris is flexible in its investment sizes.

Following completion of the transaction, which is expected to close in the second half of 2026, LS&H will operate as an independent company.